Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2009 1
2010 6
2011 23
2012 61
2013 70
2014 107
2015 123
2016 137
2017 138
2018 190
2019 170
2020 141
2021 27
Text availability
Article attribute
Article type
Publication date

Search Results

1,050 results
Results by year
Filters applied: . Clear all
Page 1
Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Van Der Weyden C, et al. Expert Rev Hematol. 2019 Jan;12(1):5-19. doi: 10.1080/17474086.2019.1558399. Epub 2018 Dec 18. Expert Rev Hematol. 2019. PMID: 30526166 Review.
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. ...Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-ce
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting a
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
Scott LJ. Scott LJ. Drugs. 2017 Mar;77(4):435-445. doi: 10.1007/s40265-017-0705-5. Drugs. 2017. PMID: 28190142 Free PMC article. Review.
In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin resulted in high objective response (complete plus partial remission) rates in patients with relapsed or refractory CD30-positive HL, including as retreatment i …
In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin resulted in high obj …
Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK, Gong JZ, Porcu P. Barta SK, et al. Blood. 2019 Dec 26;134(26):2339-2345. doi: 10.1182/blood.2019001821. Blood. 2019. PMID: 31697814
The development of brentuximab vedotin has opened a new era in the management of peripheral T-cell lymphomas (PTCLs). The improved outcomes with brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) vs cycl …
The development of brentuximab vedotin has opened a new era in the management of peripheral T-cell lymphomas (PTCLs). The impr …
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Grade 3-4 adverse events were reported in 27 (41%) of 66 patients in the brentuximab vedotin group and 29 (47%) of 62 patients in the physician's choice group. ...INTERPRETATION: Significant improvement in objective response lasting at least 4 months was seen with …
Grade 3-4 adverse events were reported in 27 (41%) of 66 patients in the brentuximab vedotin group and 29 (47%) of 62 patients …
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Moskowitz CH, et al. Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19. Lancet. 2015. PMID: 25796459 Clinical Trial.
We recorded consistent benefit (HR <1) of brentuximab vedotin consolidation across subgroups. The most frequent adverse events in the brentuximab vedotin group were peripheral sensory neuropathy (94 [56%] of 167 patients vs 25 [16%] of 160 patients …
We recorded consistent benefit (HR <1) of brentuximab vedotin consolidation across subgroups. The most frequent adverse eve …
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A. Straus DJ, et al. Blood. 2020 Mar 5;135(10):735-742. doi: 10.1182/blood.2019003127. Blood. 2020. PMID: 31945149 Clinical Trial.
The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with doxorubicin, vinblastine, and dacarbazine (AVD; A+AVD) exhibited superior modified progression-free survival (PFS) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for frontline …
The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with doxorubicin, vinblastine, and dacarbazine (AVD; A+A …
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.
PURPOSE: Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a f …
PURPOSE: Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimic …
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L, Mehta-Shah N. Shea L, et al. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19. doi: 10.1007/s11899-020-00561-w. Curr Hematol Malig Rep. 2020. PMID: 32016790 Review.
PURPOSE OF REVIEW: The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. ...
PURPOSE OF REVIEW: The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cell …
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM. Abramson JS, et al. Blood. 2019 Aug 15;134(7):606-613. doi: 10.1182/blood.2019001272. Epub 2019 Jun 11. Blood. 2019. PMID: 31186274 Clinical Trial.
Patients received a lead-in cycle of brentuximab vedotin monotherapy on days 1 and 15, followed by an exploratory positron emission tomography/computed tomography scan. ...One elderly patient died of neutropenic sepsis in the first brentuximab-AVD cycle. B
Patients received a lead-in cycle of brentuximab vedotin monotherapy on days 1 and 15, followed by an exploratory positron emi …
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F. Berger GK, et al. Crit Rev Oncol Hematol. 2017 Jan;109:42-50. doi: 10.1016/j.critrevonc.2016.11.009. Epub 2016 Nov 21. Crit Rev Oncol Hematol. 2017. PMID: 28010897 Free PMC article. Review.
BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. ...
BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to th …
1,050 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page